BioSpace News Archive

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024.

Biodexa Pharmaceuticals PLC announces $7 million of gross proceeds from the exercise of previously issued warrants and an agreement between the Company and several accredited investors to exercise certain existing Series E warrants and Series F warrants to purchase up to an aggregate of 4,358,322 of the Company’s American Depositary Shares ).

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer.

Lifecore Biomedical, Inc. announced that Lifecore has granted a restricted stock unit award with respect to 525,000 shares of its common stock and a performance stock unit award for up to 1,500,000 shares of its common stock to Paul Josephs, Lifecore’s newly hired President and Chief Executive Officer.

Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2024.

Xtant Medical Holdings, Inc. today announced that Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will participate in the 21st Annual Craig-Hallum Institutional Investor Conference on May 29 in Minneapolis.

“Currently More Than 180 Oncolytic Virus Immunotherapies Are In Clinical Trials”

AdaptHealth Corp. announced today that they will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, being held in Miami, on Wednesday, June 12, 2024, including a presentation at 9:20am ET.

Align Technology, Inc. today announced it has appointed Emory Wright, executive vice president, direct fabrication manufacturing platform, effective immediately.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on July 15, 2024, to shareholders of record as of June 14, 2024.